Global Intravenous Immunoglobulin Market Size- By Application, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Intravenous Immunoglobulin Market Introduction and Overview

According to SPER market research, 'Global Intravenous Immunoglobulin Market Size- By Application, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Intravenous Immunoglobulin Market is predicted to reach 28.52 billion by 2034 with a CAGR of 7.49%.

A blood product called intravenous immunoglobulin (IVIG) is created from pooled plasma donations and contains immunoglobulins, primarily IgG antibodies. It is used to treat a range of immune-related conditions, such as autoimmune illnesses, inflammatory disorders, and primary and secondary immunodeficiencies.

Restraints: The intravenous immunoglobulin (IVIG) market has various difficulties that limit its growth and accessibility. One major difficulty is the high capital and operating costs involved with IVIG production. The procedure entails collecting large amounts of donor plasma, followed by intensive production and testing to assure safety and efficacy. These tight procedures increase operational costs, which are then passed on to patients, reducing accessibility and affordability.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Application, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Baxter, BDI Pharma Inc., Biotest AG, China Biologics Products Inc., CSL, Grifols SA, Kedrion, LFB, Octapharma AG and others.

Global Intravenous Immunoglobulin Market Segmentation:

By Application: Based on the Application, Global Intravenous Immunoglobulin Market is segmented as; Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis and Multifocal motor neuropathy

By Distribution Channel: Based on the Distribution Channel, Global Intravenous Immunoglobulin Market is segmented as; Hospital Pharmacies, Specialty Pharmacies and Other.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Product Code: HLCA25156

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1.Global Intravenous Immunoglobulin Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Intravenous Immunoglobulin Market

7. Global Intravenous Immunoglobulin Market, By Application (USD Million) 2025-2034

7.1. Immunodeficiency diseases
7.2. CIDP
7.3. Hypogammaglobulinemia
7.4. Congenital AIDS
7.5. Chronic Lymphocytic Leukemia
7.6. Myasthenia Gravis
7.7. Multifocal motor neuropathy

8. Global Intravenous Immunoglobulin Market, By Distribution Channel (USD Million) 2025-2034

8.1. Hospital Pharmacies
8.2. Specialty Pharmacies
8.3. Other

9. Global Intravenous Immunoglobulin Market Forecast, 2025-2034 (USD Million)

9.1. Global Intravenous Immunoglobulin Market Size and Market Share

10. Global Intravenous Immunoglobulin Market, By Region, 2025-2034 (USD Million)

10.1. Asia-Pacific
- 10.1.1. Australia
- 10.1.2. China
- 10.1.3. India
- 10.1.4. Japan
- 10.1.5. South Korea
- 10.1.6. Rest of Asia-Pacific
10.2. Europe
- 10.2.1. France
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. United Kingdom
- 10.2.6. Rest of Europe
10.3. Middle East and Africa
- 10.3.1. Kingdom of Saudi Arabia
- 10.3.2. United Arab Emirates
- 10.3.3. Qatar
- 10.3.4. South Africa
- 10.3.5. Egypt
- 10.3.6. Morocco
- 10.3.7. Nigeria
- 10.3.8. Rest of Middle-East and Africa
10.4. North America
- 10.4.1. Canada
- 10.4.2. Mexico
- 10.4.3. United States
10.5. Latin America
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Rest of Latin America

11. Company Profile

11.1. Baxter
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
11.2. BDI Pharma Inc.
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
11.3. Biotest AG
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
11.4. China Biologics Products Inc.
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
11.5. CSL
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
11.6. Grifols SA
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
11.7. Kedrion
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
11.8. LFB
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
11.9. Octapharma AG
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
11.10. Others